<DOC>
	<DOCNO>NCT01696695</DOCNO>
	<brief_summary>This observational study evaluate efficacy safety different capecitabine base chemotherapy , alone combination therapy , first line treatment metastatic colorectal cancer participant everyday clinical practice .</brief_summary>
	<brief_title>An Observational Study First-Line Capecitabine Based Chemotherapy Participants With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Participants newly diagnose mCRC start firstline capecitabinebased chemotherapy accordance current Hungarian label History serious unexpected reaction fluoropyrimidine therapy Hypersensitivity active ingredient Xeloda excipients product , fluorouracil Known dihydropyrimidine dehydrogenase deficiency Pregnancy lactation Inadequate bone marrow , hepatic renal function Treatment sorivudine chemical analogue ( example , brivudine ) If contraindication drug use combination treatment schedule present , drug question use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>